PVLA Stock Analysis: Buy, Sell, or Hold?
PVLA - Palvella Therapeutics, Inc. Common Stock
$146.03
1.27 (0.88%)
▲
5d:
+4.08%
30d:
+42.9%
90d:
+14.88%
BUY
MODERATE Confidence
Analysis Updated: Jul 13, 2026 12:00 AM ET
Earnings: Aug 13, 2026
30d
Get Alerted When PVLA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called PVLA this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: PVLA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
💡 BUY OPPORTUNITY: PVLA shows positive signals but monitor for confirmation. Company currently unprofitable (negative forward earnings). Moderate conviction.
In-depth Analysis How we analyze
Valuation Analysis: PVLA is currently trading at $146.03, which is considered extended relative to its 30-day fair value range of $109.76 to $145.65.
Technical Outlook: Technically, PVLA is showing sideways momentum. Immediate support is located at $135.00, while resistance sits at $161.38.
Market Sentiment: PVLA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (1th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $229.60 (+57.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, PVLA is showing sideways momentum. Immediate support is located at $135.00, while resistance sits at $161.38.
Market Sentiment: PVLA has a strong technical setup (75/100), with favorable trendlines, momentum, and price action for short-term traders. In the options market, Implied Volatility is low (1th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Wall Street analysts see significant upside, with an average price target of $229.60 (+57.2%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$109.76 -
$145.65
Company Quality Score
61/100
(BUY)
Options IV Signal
1th percentile
(COMPLACENCY WARNING)
Volume Confirmation
HIGH
Confidence Score
70.8%
All Signals
- BEARISH: Price extended above range
- BULLISH: Options cheap (IV 1th percentile)
- BULLISH: Strong technical setup (75/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 57.2% below Wall St target ($229.60)
Trading Range Analysis
30-Day Trading Range
$109.76 -
$145.65
Current vs Trading Range
EXTENDED
Expected Move (7 Days)
±$13.39
(9.2%)
Support & Resistance Levels
Support Level
$135.00
Resistance Level
$161.38
Current Trend
Sideways
Technical data as of
Jul 13, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-21.42
Wall Street Target
$229.60
(+57.2%)
Share & Embed Analysis
Last updated: July 13, 2026 6:02 PM ET
Data refreshes hourly during market hours. Next update: 7:02 PM
Data refreshes hourly during market hours. Next update: 7:02 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is PVLA showing a specific setup today?
Insider Activity (6 Months)
2
Buys
2
Sells
0
Net
INSIDERS SELLING
Recent Transactions
Kathleen Goin
SELL
4302 shares
2026-03-18
Elaine J Heron
BUY
2400 shares
2026-02-27
George M Jenkins
BUY
4000 shares
2026-02-27
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$88 | 66 BUY |
|
SRPT
Sarepta Therapeutics Inc |
STRONG BUY
26 analysts |
$22 | 57 HOLD |
|
VRTX
Vertex Pharmaceuticals I… |
BUY
34 analysts |
$555 | 57 HOLD |
|
INCY
Incyte Corporation |
HOLD
27 analysts |
$111 | 57 HOLD |
|
CLDX
Celldex Therapeutics Inc |
STRONG BUY
15 analysts |
$58 | 62 BUY |
